Journal of the American Society of Hypertension
Volume 1, Issue 6 , Pages 373-380 , November 2007

Historical perspective of low- vs. high-dose diuretics

  • Barry J. Materson, MD, MBA

      Affiliations

    • Corresponding Author InformationCorresponding author: Barry J. Materson, MD, MBA, University of Miami Miller School of Medicine, OPPRP (D-54), P.O. Box 016960, Miami, Florida 33101. Tel: 350-243-7221; fax: 305-243-9902.

Received 5 June 2007 ,Accepted 21 June 2007.

References 

  1. Materson BJ, Johnson AE, Perez-Stable EC. Inulin labeled with chromium 51 for determination of glomerular filtration rate. JAMA. 1969;207:94–96
  2. Maher FT, Tauxe N. Renal clearance in man of pharmaceuticals containing radioactive iodine. JAMA. 1969;207:97–104
  3. Perez-Stable EC, Materson BJ. Diuretic drug therapy of edema. Med Clin North Am. 1971;55:359–372
  4. Materson BJ, Hotchkiss JL, Barkin JS, Reitberg BH, Bailey K, Perez-Stable EC. Oral Metolazone: effects on urine composition in water-loaded normal man. Curr Ther Res. 1972;14:545–560
  5. Materson BJ, Oster JR, Perez-Stable EC. Antihypertensive effects of metolazone (Zaroxolyn). Curr Ther Res. 1974;16:890–896
  6. Freis ED, Wilson IM. Potentiating effect of cholorothiazide (Diuril) in combination with antihypertensive agents: preliminary report. Med Ann Dist Columbia. 1957;26:468;516
  7. Freis ED, Wanko A, Wilson IM, Parrish AE. Treatment of essential hypertension with chlorothiazide (diuril); its use alone and combined with other antihypertensive agents. JAMA. 1958;166:137–140
  8. McMahon FG. Management of essential hypertension (The new low-dose era). 2nd ed.. Mount Kisko, New York: Futura; 1984;
  9. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: I. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967;202:1028–1034
  10. Propranolol in the treatment of essential hypertension (Veterans Administration Cooperative Study Group on Antihypertensive Agents). JAMA. 1977;237:2303–2310
  11. Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: a cooperative study. JAMA. 1977;237:255–261
  12. The 1980 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1980;140:1280–1285
  13. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension (I. Results of short-term titration with emphasis on racial differences in response. Veterans Administration Cooperative Study Group on Antihypertensive Agents). JAMA. 1982;248:1996–2003
  14. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension (II. Results of long-term therapy. Veterans Administration Cooperative Study Group on Antihypertensive Agents). JAMA. 1982;248:2004–2011
  15. The 1984 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1984;144:1045–1057
  16. Cushman WC, Khatri I, Materson BJ, Reda DJ, Freis ED, Goldstein G, et al. Treatment of hypertension in the elderly (III. Response of isolated systolic hypertension to various doses of hydrochlorothiazide: results of a Department of Veterans Affairs Cooperative Study. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents). Arch Intern Med. 1991;151:1954–1960
  17. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-drug therapy for hypertension in men (A comparison of six antihypertensive agents with placebo). N Engl J Med. 1993;328:914–921
  18. Materson BJ, Reda DJ, Cushman WC. Department of veterans Affairs single-drug therapy of hypertension study (Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents). Am J Hypertens. 1995;8:189–192
  19. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure National Heart, Lung, and Blood Institute National High Blood Pressure Education Program Coordinating Committee Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252
  20. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)). [Erratum in: JAMA 2003;289:178; JAMA 2004;291:2196] JAMA. 2002;288:2981–2997
  21. Materson BJ, Reda DJ, Cushman WC, Henderson WG. Results of combination antihypertensive therapy after failure of each of the components (Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents). J Hum Hypertens. 1995;9:791–796
  22. Cushman WC, Materson BJ, Williams DW, Reda DJ. Pulse pressure changes with six classes of antihypertensive agents in a randomized controlled trial. Hypertension. 2001;38:953–957
  23. Frishman WH, Bryzinski BS, Coulson LR, DeQuattro VL, Vlachakis ND, Mroczek WJ, et al. A multifactorial trial design to assess combination therapy in hypertension (Treatment with bisoprolol and hydrochlorothiazide). [Erratum in: Arch Intern Med 1995;155:709] Arch Intern Med. 1994;154:1461–1468
  24. Ames RP, Hill P. Elevation of serum lipids during diuretic therapy of hypertension. Am J Med. 1976;61:748–757
  25. Amery A, Berthaux P, Birkenhager W, Boel A, Brixko P, Bulpitt C, et al. Antihypertensive therapy in patient above age 60 (Third interim report of the European Working Party on High blood pressure in Elderly (EWPHE)). Acta Cardiol. 1978;33:113–134
  26. Ekbom T, Dahlof B, Hansson L, Lindholm LH, Wester PO. Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: a report from the STOP-Hypertension Study. J Hypertens. 1992;10:1525–1530
  27. Dydra I, Dufault C, Hebert J-G, Tremblay G, Genest J. Studies on a new diuretic: chlorthalidone. Can Med Assoc J. 1962;86:475–482
  28. Carney S, Gilles AL, Morgan T. Optimal dose of a thiazide diuretic. Med J Aust. 1976;2:692–693
  29. Tweeddale MG, Ogilvie RI, Ruedy J. Antihypertensive and biochemical effects of chlorthalidone. Clin Pharmacol Ther. 1977;22:519–527
  30. Materson BJ, Oster JR, Michael UF, Bolton SM, Burton ZC, Stanbaugh JE, et al. Dose response to chlorthalidone in patients with mild hypertension (Efficacy of a lower dose). Clin Pharmacol Ther. 1978;24:192–198
  31. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program (I. Reduction in mortality of persons with high blood pressure, including mild hypertension). JAMA. 1979;242:2562–2571
  32. Neaton JD, Grimm RH, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, et al. Treatment of Mild Hypertension Study Research Group JAMA. 1993;270:718–724
  33. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension (Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group). JAMA. 1991;265:3255–3264
  34. Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JJ, Phillips BB, Zimmerman MB, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352–358
  35. Sica DA. Chlorthalidone: has it always been the best thiazide-type diuretic?. Hypertension. 2006;47:321–322
  36. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide vs. chlorthalidone: evidence supporting their interchangeability. Hypertension. 2004;43:4–9
  37. Psaty BM, Lumley T, Furberg CD. Meta-analysis of health outcomes of chlorthalidone-based vs. nonchlorthalidone-based low-dose diuretic therapies. JAMA. 2004;292:43–44
  38. Witchite S, Kamoun A, Chiche P. A double-blind study in hypertensive patients of an original new compound, indapamide. Curr Med Res Opin. 1975;3:1–8
  39. Anavekar SN, Ludbrooke A, Louis WJ, Doyle AE. Evaluation of indapamide in the treatment of hypertension. J Cardiovasc Pharmacol. 1979;1:389–394
  40. Capone P, Vukovich RA, Neiss ES, Bolton S, Reeves RL. Multicenter dose-response study of the effect of indapamide in the treatment of patients with mild to moderate hypertension. Clin Ther. 1983;5:305–316
  41. Mallion JM, Asmar R, Boutelant S, Guez D. Twenty-four hour antihypertensive efficacy of indapamide, 1.5 mg sustained release: results of two randomized double-blind controlled studies. J Cardiovasc Pharmacol. 1998;32:673–678
  42. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925–930
  43. Goodfriend TL. Treating resistant hypertension with a neglected old drug. Hypertension. 2007;49:763–764
  44. Dupont AG, Schoors D, Six RO, Vanhaelst L. Antihypertensive efficacy of low-dose torasemide in essential hypertension: a placebo-controlled study. J Hum Hypertens. 1988;2:265–268

 Conflict of interest: none.

PII: S1933-1711(07)00150-7

doi: 10.1016/j.jash.2007.06.007

Journal of the American Society of Hypertension
Volume 1, Issue 6 , Pages 373-380 , November 2007

Article Tools

* Image Usage & Resolution